---
title: "Weekly Recap | Cigna +1.31%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298096937.md"
description: "Cigna (CI) rose 1.31% this week to close at $282.52, outperforming the S&P 500 by roughly 1.22 percentage points. Trading was choppy: the stock opened lower on Monday, dipped to a weekly low of $275.59, then bounced from Tuesday, peaked at $286.81 on Thursday, and settled back to $282.52 on Friday. The weekly range was 4.02%. Daily volume averaged 1.42m shares, about 1.52% below the 60-day median, so turnover stayed moderate."
datetime: "2026-09-05T06:37:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298096937.md)
  - [en](https://longbridge.com/en/news/298096937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298096937.md)
generator: "portal-rs"
---

# Weekly Recap | Cigna +1.31%, most brokers rate it buy

## The Week

Cigna (CI) rose 1.31% this week to close at $282.52, outperforming the S&P 500 by roughly 1.22 percentage points. Trading was choppy: the stock opened lower on Monday, dipped to a weekly low of $275.59, then bounced from Tuesday, peaked at $286.81 on Thursday, and settled back to $282.52 on Friday. The weekly range was 4.02%. Daily volume averaged 1.42m shares, about 1.52% below the 60-day median, so turnover stayed moderate.

## Key Events

There were no major company filings or regulatory updates this week. News flow skewed towards industry and market comparisons. On 31 August, the Roxbury Institute announced in-network Cigna access starting 15 October for eligible patients seeking specialised lipedema care in California. On 1-2 September, market briefs compared Cigna with peers across healthcare plans, noting underperformance on Monday and outperformance on Tuesday. On 2 September, Bill Ackman backed Mark Cuban’s drug pricing model, with healthcare stocks mentioned as potential winners or losers. On 3 September, a long-term return piece highlighted the cumulative return on $100 invested 20 years ago.

## Analyst Ratings

As of this week, 24 institutions cover Cigna: 13 rate it buy, 6 overweight, and 5 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $341.42, about 20.85% above the weekly close. Targets range from $290 to $400, suggesting meaningful dispersion. Among 53 healthcare services companies, Cigna ranks third by analyst rating.

## The Week Ahead

US macro data dominates 8-10 September. On 8 September, the NFIB Small Business Optimism Index is due. On 10 September, a busier slate includes initial jobless claims, final demand PPI and its core ex-food-and-energy reading, existing home sales, wholesale sales, EIA natural gas storage change, and the 10-year Treasury auction’s high yield and bid-to-cover ratio. Healthcare services remain sensitive to rates and inflation, so Treasury yields and PPI prints are worth tracking.

## In Short

Cigna beat the broader market this week. The consensus rating stays at buy, with the consensus target about 20.85% above spot, and the stock ranks high within its industry. Valuation sits at roughly 11.6x P/E and 1.75x P/B, with a dividend yield around 2.17%. On the latest trading day, retail investors were net buyers while large-lot money turned slightly net seller. The focus now shifts to the 10-year yield and inflation data, and how they affect healthcare services valuations.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CI.US](https://longbridge.com/en/quote/CI.US.md)

## Related News & Research

- [HighTower Advisors LLC Boosts Stock Position in Cigna Group $CI](https://longbridge.com/en/news/298200797.md)
- [Cigna (CI) Stock Still Looks Cheap After a 51% Five Year Run](https://longbridge.com/en/news/298347426.md)
- [Chile 10Y Bond Yield Hits 14-month High](https://longbridge.com/en/news/298233809.md)
- [Treasury yields face 4.8% test as fiscal risks threaten to spill into other assets](https://longbridge.com/en/news/298154920.md)
- [Cigna EVP, Special Advisor to CEO Neville Everett disposes of 617 common shares worth $175,259.85](https://longbridge.com/en/news/298361964.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**